Valuation Novartis AG

Equities

Market Closed - Swiss Exchange Other stock markets 10:01:52 16/01/2026 pm IST			5-day change	1st Jan Change
115.60 ^CHF	+0.98%		+1.37%	+5.47%

16/01	Novartis Ianalumab Receives Fda Breakthrough Therapy Designation for Sjogren's Disease	CI
16/01	Novartis Receives US FDA Breakthrough Therapy Designation for Ianalumab to Treat Sjogren's Disease	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	2,15,322	1,96,458	1,94,448	2,07,167	1,95,514	2,76,384	2,76,384	-
Change	-	-8.76%	-1.02%	6.54%	-5.62%	41.36%	0%	-
Enterprise Value (EV) ¹	2,39,822	2,04,649	2,03,482	2,19,178	2,13,458	2,97,357	3,00,826	2,96,998
Change	-	-14.67%	-0.57%	7.71%	-2.61%	39.3%	1.17%	-1.27%
P/E ratio	26.7x	8.2x	28.3x	14.1x	16.5x	20x	19.4x	17.7x
PBR	3.78x	2.9x	3.23x	4.41x	4.52x	6.45x	5.88x	5.37x
PEG	-	0x	-0.4x	0x	-1x	0.9x	6.64x	1.82x
Capitalization / Revenue	4.43x	3.81x	3.85x	4.44x	3.78x	4.97x	4.85x	4.65x
EV / Revenue	4.93x	3.96x	4.03x	4.7x	4.13x	5.35x	5.27x	5x
EV / EBITDA	14.2x	11.2x	10.9x	12.2x	10.2x	12.5x	12.7x	11.9x
EV / EBIT	15.6x	12.3x	12.2x	13.4x	10.9x	13.6x	13.7x	12.8x
EV / FCF	20.5x	15.4x	17x	16.6x	13.1x	21.2x	20.1x	18.6x
FCF Yield	4.87%	6.49%	5.87%	6.01%	7.61%	4.71%	4.99%	5.36%
Dividend per Share ²	3.375	3.36	3.5	3.823	3.856	4.1	4.264	4.465
Rate of return	3.57%	3.83%	3.87%	3.79%	3.94%	2.85%	2.96%	3.1%
EPS ²	3.55	10.71	3.19	7.15	5.92	7.203	7.413	8.132
Distribution rate	95.1%	31.4%	110%	53.5%	65.1%	56.9%	57.5%	54.9%
Net sales ¹	48,659	51,626	50,545	46,660	51,722	55,613	57,034	59,390
EBITDA ¹	16,845	18,246	18,613	17,937	21,006	23,739	23,653	25,036
EBIT ¹	15,416	16,588	16,665	16,372	19,494	21,854	21,896	23,227
Net income ¹	8,072	24,021	6,955	14,854	11,939	14,262	14,261	15,634
Net Debt ¹	24,500	8,191	9,034	12,011	17,944	20,973	24,441	20,613
Reference price ²	94.67	87.82	90.40	100.79	97.79	144.04	144.04	144.04
Nbr of stocks (in thousands)	22,74,506	22,37,092	21,50,980	20,55,460	19,99,270	19,18,792	19,18,792	-
Announcement Date	26/01/21	02/02/22	01/02/23	31/01/24	31/01/25	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
NOVARTIS AG	20x	5.35x	12.53x	2.85%	28TCr
ELI LILLY AND COMPANY	45.31x	15.02x	33.36x	0.57%	93TCr
JOHNSON & JOHNSON	21.16x	5.89x	16.37x	2.36%	53TCr
ABBVIE INC.	63.59x	7.14x	17.12x	3.05%	38TCr
ROCHE HOLDING AG	20.49x	5.08x	12.65x	2.84%	37TCr
ASTRAZENECA PLC	28.83x	5.35x	15.87x	1.73%	29TCr
MERCK & CO., INC.	13.94x	4.57x	9.84x	2.97%	27TCr
NOVO NORDISK A/S	16.84x	5.95x	12.3x	2.99%	27TCr
AMGEN INC.	25.84x	6.13x	10.48x	2.89%	18TCr
GILEAD SCIENCES, INC.	18.61x	5.75x	10.49x	2.66%	15TCr
Average	27.46x	6.62x	15.10x	2.49%	36.46TCr
Weighted average by Cap.	31.45x	8.09x	18.75x	2.14%